BIOMAT Database Logo BIOMAT Database Logo

SMAD4 is a potential prognostic marker in human breast carcinomas. 2014

Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, China, liunn1976@163.com.

SMAD4 is a downstream mediator of transforming growth factor beta. While its tumor suppressor function has been investigated as a prognostic biomarker in several human malignancies, its role as a prognostic marker in breast carcinoma is still undefined. We investigated SMAD4 expression in breast carcinoma samples of different histologic grades to evaluate the association between SMAD4 and outcome in breast cancer. We also investigated the role of SMAD4 expression status in MDA-MB-468 breast cancer cells in responding to TGF-β stimulation. SMAD4 expression was assessed in 53 breast ductal carcinoma samples and in the surrounding normal tissue from 50 of the samples using immunohistochemistry, Western blot, and real-time PCR. TGF-β-SMAD and non-SMAD signaling was assessed by Western blot in MDA-MB-468 cells with and without SMAD4 restoration. SMAD4 expression was reduced in ductal breast carcinoma as compared to surrounding uninvolved ductal breast epithelia (p < 0.05). SMAD4 expression levels decreased from Grade 1 to Grade 3 ductal breast carcinoma as assessed by immunohistochemistry (p < 0.05). Results were recapitulated by tissue array. In addition, immunohistochemistry results were further confirmed at the protein and mRNA level. We then found that non-SMAD MEK/MAPK signaling was significantly different between SMAD4 expressing MDA-MB-468 cells and SMAD4-null MDA-MB-468 cells. This is the first study indicating that SMAD4 plays a key role in shifting MAPK signaling. Further, we have demonstrated that SMAD4 has a potential role in the development of breast carcinoma and SMAD4 was a potential prognostic marker of breast carcinoma. Our findings further support the role of SMAD4 in breast carcinoma development. In addition, we observed an inverse relationship between SMAD4 levels and breast carcinoma histological grade. Our finding indicated that SMAD4 expression level in breast cancer cells played a role in responding non-SMAD signaling but not the canonic SMAD signaling. Further mechanistic studies are necessary to establish the role of SMAD4 in breast carcinoma prognosis and potential specific targeting.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer.
November 2013, Journal of cancer research and clinical oncology,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
BRG1 is a prognostic marker and potential therapeutic target in human breast cancer.
January 2013, PloS one,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
SMAD4 as a prognostic marker in colorectal cancer.
April 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
Overexpression of FOXM1 Is a Potential Prognostic Marker in Male Breast Cancer.
January 2017, Oncology research and treatment,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer.
January 2017, PloS one,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas.
April 2004, Annals of oncology : official journal of the European Society for Medical Oncology,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
HIF-1alpha is a prognostic marker in oral squamous cell carcinomas.
January 2010, The International journal of biological markers,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
Moesin expression is a marker of basal breast carcinomas.
October 2007, International journal of cancer,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer.
January 2008, Breast cancer research : BCR,
Nan-nan Liu, and Yue Xi, and Michael U Callaghan, and Andrew Fribley, and Lakisha Moore-Smith, and Jacquelyn W Zimmerman, and Boris Pasche, and Qinghua Zeng, and Yu-lin Li
Cyclin E, a potential prognostic marker for breast cancer.
January 1994, Cancer research,
Copied contents to your clipboard!